Mammalian Target of Rapamycin: Is It Relevant to COPD Pathogenesis or Treatment?

References

• Shimobayashi M, Hall MN. Making new contacts: the mTOR network in metabolism and signalling crosstalk. Nat Rev Mol Cell Biol. 2014;15(3):155–162. doi:10.1038/nrm3757.
   PubMed Web of Science ®Google Scholar
• Flati V, Corsetti G, Pasini E, et al. Nutrition, nitrogen requirements, exercise and chemotherapy-induced toxicity in cancer patients. A puzzle of contrasting truths? Anticancer Agents Med Chem. 2016;16(1):89–100. doi:10.2174/1871520615666150824152900.
   PubMed Web of Science ®Google Scholar
• Kim YC, Guan KL. mTOR: a pharmacologic target for autophagy regulation. J Clin Invest. 2015;125(1):25–32. doi:10.1172/JCI73939.
   PubMed Web of Science ®Google Scholar
• Foster KG, Fingar DC. Mammalian target of rapamycin (mTOR): conducting the cellular signaling symphony. J Biol Chem. 2010;285(19):14071–14077. doi:10.1074/jbc.R109.094003.
   PubMed Web of Science ®Google Scholar
• Hara K, Maruki Y, Long X, et al. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell. 2002;110(2):177–189.
   PubMed Web of Science ®Google Scholar
• Carracedo A, Ma L, Teruya-Feldstein J, et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest. 2008;118(9):3065–3074. doi:10.1172/jci34739.
   PubMed Web of Science ®Google Scholar
• Garber K. Targeting mTOR: something old, something new. J Natl Cancer Inst. 2009;101(5):288–290. doi:10.1093/jnci/djp034.
   PubMedGoogle Scholar
• Sarbassov DD, Ali SM, Kim DH, et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol. 2004;14(14):1296–1302. doi:10.1016/j.cub.2004.06.054.
   PubMed Web of Science ®Google Scholar
• Jacinto E, Facchinetti V, Liu D, et al. SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell. 2006;127(1):125–137. doi:10.1016/j.cell.2006.08.033.
   PubMed Web of Science ®Google Scholar
• Yang Y, Bardeleben C, Frost P, et al. DEPTOR is linked to a TORC1-p21 survival proliferation pathway in multiple myeloma cells. Genes Cancer. 2014;5(11–12):407–419. doi:10.18632/genesandcancer.44.
   PubMedGoogle Scholar
• Mihaylova MM, Shaw RJ. The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nat Cell Biol. 2011;13(9):1016–1023. doi:10.1038/ncb2329.
   PubMed Web of Science ®Google Scholar
• Averous J, Lambert-Langlais S, Carraro V, et al. Requirement for lysosomal localization of mTOR for its activation differs between leucine and other amino acids. Cell Signal. 2014;26(9):1918–1927. doi:10.1016/j.cellsig.2014.04.019.
   PubMed Web of Science ®Google Scholar
• Vlahakis A, Graef M, Nunnari J, et al. TOR complex 2-Ypk1 signaling is an essential positive regulator of the general amino acid control response and autophagy. Proc Natl Acad Sci USA. 2014;111(29):10586–10591. doi:10.1073/pnas.1406305111.
   PubMed Web of Science ®Google Scholar
• Bernard M, Dieudé M, Yang B, et al. Autophagy fosters myofibroblast differentiation through MTORC2 activation and downstream upregulation of CTGF. Autophagy. 2014;10(12):2193–2207. doi:10.4161/15548627.2014.981786.
   PubMed Web of Science ®Google Scholar
• Gurusamy N, Lekli I, Mukherjee S, et al. Cardioprotection by resveratrol: a novel mechanism via autophagy involving the mTORC2 pathway Cardiovasc Res. 2010; 86(1):103–112. doi:10.1093/cvr/cvp384.
   PubMed Web of Science ®Google Scholar
• Boutouja F, Stiehm CM, Platta HW. mTOR: a cellular regulator interface in health and disease. Cells. 2019;8(1):pii: E18. doi:10.3390/cells8010018.
   Web of Science ®Google Scholar
• Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov. 2006;5(8):671–688. doi:10.1038/nrd2062.
   PubMed Web of Science ®Google Scholar
• Kennedy BK, Pennypacker JK. Mammalian target of rapamycin: a target for (lung) diseases and aging. Ann Am Thorac Soc. 2016;13(5 Suppl.):S398–S401. doi:10.1513/AnnalsATS.201609-680AW.
   PubMedGoogle Scholar
• Jin X, Dai H, Ding K, et al. Rapamycin attenuates bleomycin-induced pulmonary fibrosis in rats and the expression of metalloproteinase-9 and tissue inhibitors of metalloproteinase-1 in lung tissue. Chin Med J (Engl). 2014;127(7):1304–1309.
   PubMed Web of Science ®Google Scholar
• Madala SK, Maxfield MD, Davidson CR, et al. Rapamycin regulates bleomycin-induced lung damage in SP-C-deficient mice. Pulm Med. 2011;2011:653524. doi:10.1155/2011/653524.
   PubMedGoogle Scholar
• Malouf MA, Hopkins P, Snell G, et al. Everolimus in IPF study investigators. An investigator-driven study of everolimus in surgical lung biopsy confirmed idiopathic pulmonary fibrosis. Respirology. 2011;16(5):776–783. doi:10.1111/j.1440-1843.2011.01955.x.
   PubMed Web of Science ®Google Scholar
• Franceschi C, Bonafè M, Valensin S, et al. Inflamm-aging. An evolutionary perspective on immunosenescence. Ann N Y Acad Sci. 2000;908:244–254.
   PubMed Web of Science ®Google Scholar
• Houssaini A, Breau M, Kebe K, et al. mTOR pathway activation drives lung cell senescence and emphysema. JCI Insight. 2018;3(3):pii: 93203. doi:10.1172/jci.insight.93203.
   Web of Science ®Google Scholar
• Mitani A, Ito K, Vuppusetty C, et al. Restoration of corticosteroid sensitivity in chronic obstructive pulmonary disease by inhibition of mammalian target of rapamycin. Am J Respir Crit Care Med. 2016;193(2):143–153. doi:10.1164/rccm.201503-0593OC.
   PubMed Web of Science ®Google Scholar
• Wang Y, Liu J, Zhou JS, et al. MTOR suppresses cigarette smoke-induced epithelial cell death and airway inflammation in chronic obstructive pulmonary disease. J Immunol. 2018;200(8):2571–2580. doi:10.4049/jimmunol.1701681.
   PubMed Web of Science ®Google Scholar
• Duran I, Goebell PJ, Papazisis K, et al. Drug-induced pneumonitis in cancer patients treated with mTOR inhibitors: management and insights into possible mechanisms. Expert Opin Drug Saf. 2014;13(3):361–372. doi:10.1517/14740338.2014.888056.
   PubMed Web of Science ®Google Scholar
• Buron F, Malvezzi P, Villar E, et al. Profiling sirolimus-induced inflammatory syndrome: a prospective tricentric observational study. PLoS One. 2013;8(1):e53078. doi:10.1371/journal.pone.0053078.
   PubMed Web of Science ®Google Scholar
• Thoreen CC, Sabatini DM. Rapamycin inhibits mTORC1, but not completely. Autophagy. 2009;5(5):725–726. doi:10.4161/auto.5.5.8504.
   PubMed Web of Science ®Google Scholar